ORPHA:398961
Mucinous adenocarcinoma of ovary
Also known as: Ovarian mucinous adenocarcinoma
Publications
2,162
94th percentile
Trials
22
Interventional, condition-specific
Researchers
1,209
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Mucinous adenocarcinoma of ovary is a rare, malignant epithelial tumor of the ovary characterized, macroscopically, by a large, usually unilateral tumor with smooth surface and evenly distributed cystic and solid areas and, histologically, by a complex papillary growth pattern with microscopic cystic glands and necrotic debris. Patients often present with pelvic pain and pressure, abdominal mass or gastrointestinal problems such as early satiety or bloating.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005601
- UMLS:C1335167
- NCIT:C5243
Additional Mondo synonyms (7)
mucinous adenocarcinoma of ovary · mucinous adenocarcinoma of the ovary · mucinous carcinoma of ovary · mucinous carcinoma of the ovary · ovarian mucinous adenocarcinoma · ovarian mucinous carcinoma · ovary mucinous adenocarcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,162 matched papers (1,263 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
22 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,162
2,162 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,162 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
1,263 in the last 10 years · high confidence · 94th percentile (publications denominator)
Phrase hits: 2,162 · MeSH hits: 0
Who's working on it?
1,209
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Bernreuther C6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 02Burandt E6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 03Clauditz TS6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 04Fraune C6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 05Hinsch A6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 06Hube-Magg C6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 07Jacobsen F6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 08Kluth M6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 09Krech T6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC - 10Lebok P6 papers · 2026
Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
22
interventional trials for this specific condition
22 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 41 trials are registered for mucinous adenocarcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
22 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.8th percentile).
high confidence · 94.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
22 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05415709·RECRUITING·Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Conditions: Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma · Ovarian Endometrioid Adenocarcinoma·Matched via name phrase
- NCT05500391·RECRUITING·Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Conditions: Stage I Testicular Seminoma · Stage I Testicular Nonseminomatous Germ Cell Tumor · Gastrointestinal Stromal Tumors · Ovarian Germ Cell Tumor·Matched via name phrase
Broader category: mucinous adenocarcinoma
41
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05112601·RECRUITING·Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Conditions: Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT07454031·NOT YET RECRUITING·Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma
Conditions: Peritoneal (Metastatic) Cancer·Matched via name phrase
- NCT07665684·NOT YET RECRUITING·Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Conditions: Pancreas Ductal Adenocarcinoma · Pancreas Cancer, Metastatic · Pancreatic Adenocarcinoma Metastatic · Adenosquamous Carcinoma of the Pancreas·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mucinous adenocarcinoma of ovary" OR "Mucinous adenocarcinoma of the ovary" OR "Ovarian mucinous adenocarcinoma" OR "mucinous carcinoma of ovary" OR "mucinous carcinoma of the ovary" OR "ovarian mucinous carcinoma" OR "ovary mucinous adenocarcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mucinous adenocarcinoma of ovary" OR "Mucinous adenocarcinoma of the ovary" OR "Ovarian mucinous adenocarcinoma" OR "mucinous carcinoma of ovary" OR "mucinous carcinoma of the ovary" OR "ovarian mucinous carcinoma" OR "ovary mucinous adenocarcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 22 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"mucinous adenocarcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:21:42.254Z